Biomarker-guided stratification of autoimmune patients for biologic therapy

被引:4
|
作者
Ivison, Sabine [1 ,2 ]
Des Rosiers, Christine [3 ,4 ]
Lesage, Sylvie [3 ,5 ]
Rioux, John D. [3 ,4 ]
Levings, Megan K. [1 ,2 ]
机构
[1] Univ British Columbia, Dept Surg, Vancouver, BC, Canada
[2] BC Childrens Hosp, Res Inst, Vancouver, BC, Canada
[3] Univ Montreal, Montreal, PQ, Canada
[4] Inst Cardiol Montreal, Montreal, PQ, Canada
[5] Hop Maison Neuve Rosemont, Montreal, PQ, Canada
基金
加拿大健康研究院;
关键词
HUMAN IMMUNE-SYSTEM; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; PREDICTS RESPONSE; PERIPHERAL-BLOOD; ULCERATIVE-COLITIS; WHOLE-BLOOD; DISEASE; STIMULATION; TOCILIZUMAB;
D O I
10.1016/j.coi.2017.09.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Autoimmunity results from an intersection of genetic and environmental factors that cause patient-specific perturbations in immune homeostasis. Defining autoimmunity-associated genetic factors has led to mechanistic insight into underlying etiologies, and the development of many biologic therapies that target the immune system. However, biomarker-informed pairing of patients with optimal biologic therapy is lacking. Here, we discuss platforms commonly used to find biomarkers that predict response to biologic therapy in autoimmunity and highlight recent biomarker discoveries. We also outline how the lack of assay standardization is a barrier to successful biomarker validation. Finally, we argue that the successful development of companion biomarkers for biologic therapy requires collaborative approaches that integrate multiple platforms and enable comprehensive measurement of multiple immune pathways.
引用
收藏
页码:56 / 63
页数:8
相关论文
共 50 条
  • [31] Precision Psychiatry: Biomarker-Guided Tailored Therapy for Effective Treatment and Prevention in Major Depression
    Jones, Candace
    Nemeroff, Charles B.
    MAJOR DEPRESSIVE DISORDER: RETHINKING AND UNDERSTANDING RECENT DISCOVERIES, 2021, 1305 : 535 - 563
  • [32] The potential impact of biomarker-guided triage decisions for patients with urinary tract infections
    A. Litke
    R. Bossart
    K. Regez
    U. Schild
    M. Guglielmetti
    A. Conca
    P. Schäfer
    B. Reutlinger
    B. Mueller
    W. C. Albrich
    Infection, 2013, 41 : 799 - 809
  • [33] The potential impact of biomarker-guided triage decisions for patients with urinary tract infections
    Litke, A.
    Bossart, R.
    Regez, K.
    Schild, U.
    Guglielmetti, M.
    Conca, A.
    Schaefer, P.
    Reutlinger, B.
    Mueller, B.
    Albrich, W. C.
    INFECTION, 2013, 41 (04) : 799 - 809
  • [34] Effects of biomarker diagnostic accuracy on biomarker-guided phase 2 trials
    Park, Jay J. H.
    Harari, Ofir
    Dron, Louis
    Mills, Edward J.
    Thorlund, Kristian
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 15
  • [35] Acute Kidney Injury: Biomarker-Guided Diagnosis and Management
    Yoon, Soo-Young
    Kim, Jin-Sug
    Jeong, Kyung-Hwan
    Kim, Su-Kang
    MEDICINA-LITHUANIA, 2022, 58 (03):
  • [36] Reducing the risk of failure: biomarker-guided trial design
    Michael J. Townsend
    Joseph R. Arron
    Nature Reviews Drug Discovery, 2016, 15 : 517 - 518
  • [37] Biomarker-guided antibiotic stewardship in neonatology: time for implementation?
    Van Wyk, Lizelle
    Lloyd, Lizel G.
    PEDIATRIC RESEARCH, 2025,
  • [38] Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development
    Stenvang, Jan
    Kumler, Iben
    Nygard, Sune Boris
    Smith, David Hersi
    Nielsen, Dorte
    Brunner, Nils
    Moreire, Jose M. A.
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [39] Evaluating statistical characteristics of biomarker-guided trial designs
    Miranta Antoniou
    Andrea Jorgensen
    Ruwanthi Kolamunnage-Dona
    Trials, 16
  • [40] Reducing the risk of failure: biomarker-guided trial design
    Townsend, Michael J.
    Arron, Joseph R.
    NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (08) : 517 - 518